Entries by achilles

ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER

Stevenage, UK; 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors. In addition, Dr Iraj Ali, currently Interim CEO, will become the permanent, full-time CEO of the Company. […]

ACHILLES ANNOUNCES APPOINTMENT OF IMMUNO-ONCOLOGY INDUSTRY LEADER, MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS

Stevenage, 19 September 2018 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens, today announced that it has appointed senior pharmaceutical executive Michael F. Giordano, M.D., to its Board of Directors. Dr. Iraj Ali, Achilles’ Chief Executive Officer, commented: “We are delighted to welcome Michael Giordano to our Board of […]